<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00161954</url>
  </required_header>
  <id_info>
    <org_study_id>225</org_study_id>
    <nct_id>NCT00161954</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years</brief_title>
  <official_title>Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      The objective of this study is to establish the earliest time point at which vaccines are
      expected to show seropositive antibody levels after vaccination with FSME-IMMUN 0.5 mL using
      a rapid immunization schedule (2 vaccinations administered 12 +/- 2 days apart.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date>May 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Encephalitis, Tick-borne</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Understanding the nature of the study, agreement to its provisions and written
             informed consent

          -  Written informed consent of subjectÂ´s parents / legal guardians (if subject is under
             18 years of age)

          -  Aged &gt;= 16 years (from the 16th birthday) to &lt;= 65 years (to the last day before the
             66th birthday)

          -  Clinically healthy, (i. e. the physician would have no reservations vaccinating with
             FSME-IMMUN 0.5 ml outside the scope of a clinical trial)

          -  Negative pregnancy test result at the first medical examination (if female and capable
             of bearing children)

          -  Agreeing to employ adequate birth control measures for the duration of the study (if
             female and capable of bearing children)

          -  Agreeing to keep a subject diary.

        Exclusion Criteria:

          -  History of any previous TBE vaccination

          -  History of TBE infection

          -  History of infection with other flaviviruses

          -  History of vaccination against yellow fever and/or Japanese B-encephalitis

          -  History of allergic reactions, in particular to one of the components of the vaccine

          -  Suffering from a disease (e.g. autoimmune disease) or undergoing a form of treatment
             (e.g. systemic corticosteroids) that can be expected to influence immunological
             functions

          -  Known or suspected problem with drug or alcohol abuse (&gt; 4 liters wine / week or
             equivalent level of other alcoholic beverages)

          -  Donation of blood or plasma within one month of study start

          -  Having received a blood transfusion or immunoglobulins within one month of study entry

          -  HIV positivity (an HIV test is not required specifically for the purpose of this study

          -  Simultaneous participation in another clinical trial including administration of an
             investigational product

          -  Participating in any other clinical study within six weeks prior to study start

          -  Participated in another Baxter vaccine study within the last six months (with the
             exception of follow-up studies)

          -  Pregnancy or lactation (if female)

          -  Having received any other vaccination within two weeks prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baxter BioScience Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baxter BioScience</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS Biopharma Research Unit Stuivenberg</name>
      <address>
        <city>Antwerp</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2005</study_first_posted>
  <last_update_submitted>May 20, 2015</last_update_submitted>
  <last_update_submitted_qc>May 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2015</last_update_posted>
  <keyword>Tick-Borne Encephalitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Encephalitis, Tick-Borne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

